LaFleur J, et al. - Researchers performed a comparison of bone adverse outcomes among treatment-naïve HIV-infected US veterans initiating efavirenz (EFV)-containing Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) regimens vs those initiating non-EFV-containing TDF/FTC regimens. In this work, EFV + TDF/FTC was observed to be associated with a lower incidence of bone adverse outcomes, including osteoporosis, any major fracture, vertebral fracture, and wrist/forearm fracture, compared with other TDF/FTC-containing regimens in the VHA. The third agent in antiretroviral regimens could have a significant effect on the risk of bone adverse events associated with TDF.